2018
San Antonio Breast Cancer Symposium (SABCS)
December 4-8, 2018 | San Antonio, TX
American Society of Clinical Oncology (ASCO)
June 1-5, 2018 | Chicago, IL
American Society of Clinical Oncology, Genitourinary (ASCO GU)
February 8-10, 2018 | San Francisco, CA
2017
San Antonio Breast Cancer Symposium (SABCS)
December 5-9, 2017 | San Antonio, TX
European Society of Medical Oncology (ESMO)
September 8-12, 2017 | Madrid, ESP
American Society of Clinical Oncology (ASCO)
June 2-6, 2017 | Chicago, IL
Citation: Cancer Res 2017; 77 (4 Suppl) Abstract P2-08-04
Title: Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01
Authors: Gucalp A, Danso MA, Elias AD, Bardia A, Ali H, Potter D, Gabrail NY, Haley BB, Khong HT, Riley EC, Ervin L, Eisner JR, Baskin-Bey, E M.D., Moore WR, Traina TA
American Society of Clinical Oncology, Genitourinary (ASCO GU)
February 16-18, 2017 |Orlando, FL
2016
San Antonio Breast Cancer Symposium (SABCS)
December 6-10, 2016| San Antonio, TX
Citation: Cancer Res 2017; 77 (4 Suppl) Abstract P2-08-04
Title: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
Authors: Gucalp A, Bardia A, Gabrail N, DaCosta N, Danso M, Elias AD, Ali H, Lemon SJ, Riley EC, Eisner JR, Fleming RA, Kurman MR, Moore WR, Traina TA.
PCF`s 23rd Annual Scientific Retreat
October 27-29, 2016| Carlsbad, CA
Edwina Baskin-Bey, CMO
William Moore, CEO
Canaccord Genuity Growth Conference
August 10-11, 2016 | Boston, MA
Innocrin Company Presentation
William Moore, CEO
American Society of Clinical Oncology (ASCO)
June 3-7, 2016 | Chicago, IL
Citation: J Clin Oncol 2016; 34 (15 Suppl) Abstract 1088
Session: Breast Cancer “ Triple Negative/Cytotoxics/Local Therapy, 6/5/2016 8:00-11:30
Title: Phase (Ph) 1 study of oral Seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).
Authors: A Bardia, N DaCosta, N Gabrail, SJ Lemon, M Danso, H Ali, R Fleming, MR Kurman, JR Eisner, WR Moore, A Gucalp, TA Traina
Center for Entrepreneurial Development (CED) Life Sciences Conference
March 1-2, 2016 | Raleigh, NC
Innocrin Company Presentation
Presentation can be viewed at:
Presentation at CED Conference
William Moore, CEO
American Society of Clinical Oncology, Genitourinary (ASCO GU)
January 7-10, 2016 | San Francisco, CA
Citation: J Clin Oncol 34, 2016 (suppl 2S; abstr 198)
Title: Cardiovascular Safety Profile of VT-464 in Patients (Pts) with Castrate-Resistant Prostate Cancer (CRPC). Â
Authors: M Kurman, P Sager, M Rudoltz, J Eisner, D Goodman, E Heyman, D Salvail, C Bell, W Moore
Citation: J Clin Oncol 34, 2016Â (suppl 2S; abstr 273)
Title: Efficacy of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.
Authors: L Nordquist, N Shore, J de Bono, S Gupta, W Berry, S Gillessen, G Liu, N Vogelzang, E Efstathiou, M Fleming, D George, J Arujo, J-S Zhang, M Kurman, J Eisner, W Moore
Citation: J Clin Oncol 34, 2016 (suppl 2S; abstr 343)
Title: Once-nightly (QD) dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464 in patients with CRPC
Authors: N Shore, L Nordquist, S Gupta, M Fleming, W Berry, JS Zhang, M Kurman, J Eisner, W Moore
2015
San Antonio Breast Cancer Symposium (SABCS)
December 8-12, 2015 | San Antonio, TX
Citation: Cancer Res 2016;76(4 Suppl):Abstract nr OT2-01-03.
Title: A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC).
Authors: A Gucalp A, C Hudis, L Norton, S Pat, MR Kurman, JR Eisner, WR Moore, TA Traina
Citation: Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-04.
Title: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) Antagonist VT-464, on AR+ and ER+ tumor models in vitro and in vivo.
Authors: SJ Ellison, JD Norris, S Wardell, JR Eisner, WJ Hoekstra, DB Stagg, HM Alley, WR Moore, DP McDonnell
Southeast BIO Investor and Partnering Forum
Nov 11-13, 2015 | Charleston, SC
Innocrin Company Presentation
William Moore, CEO
22nd Annual Prostate Cancer Foundation (PCF) Annual Retreat
October 7-10 2015 | Washington, DC
Title: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer (CRPC) Progressing on Enzalutamide (ENZ) or Abiraterone Acetate (AA).
Authors: H Scher, B Montgomery, M-E Taplin, EA Mostaghel, W Abida, M Kurman, JR Eisner, WR Moore
American Society of Clinical Oncology, Genitourinary (ASCO GU)
February 26-28, 2015 | Orlando, FL
Citation: J Clin Oncol 33, 2015 (suppl 7; abstr 187)
Title: The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.
Authors: JS De Bono, CJ Pezaro, S Gillessen, ND Shore, LT Nordquist, E Efstathiou, JC Araujo, WR Berry, G Liu, NJ Vogelzang, AG Omlin, RJ Schotzinger, JR Eisner, WR Moore
Citation: J Clin Oncol 33, 2015 (suppl 7; abstr 263)
Title: Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.
Authors: WR Moore, JD Norris, S Wardell, JR Eisner, WJ Hoekstra, RJ Schotzinger, DP McDonnell